113年7月份中部地區消化系同好會

講師:莊伯恒主任。大里仁愛醫院。胃腸肝膽科。

講題:Why BCLC A HCCs need subsequent lenvatinib after focal therapy ?

摘要:We will present you two patients, who presented with high tumor markers after initial laparoscopic resection or RFA and needed subsequent systemic therapy, one with lenvtinib and another with lenvatinib and adding atezolizumab and bevacizumab.

講師:李少武助理教授。台中榮民總醫院。胃腸肝膽科。

講題:Crucial factors impact the first-line unresectable HCC therapies under Taiwan reimbursement

摘要:Agents, including sorafenib, lenvatinib, and atezolizumab with bevacizumab were supported by Taiwan reimbursement currently. The topic was to discuss the crucial factors impact the first-line unresectable HCC therapies under Taiwan.

座長:莊伯恒主任

大里仁愛醫院
胃腸肝膽科

講師:黃挺碩教授(副院長)。大里仁愛醫院。一般外科

講題:Robotic hepato-biliary-pancreatic (HBP) surgery

摘要:Robotic surgery, using da Vinci robotic system, combined with indocyanine green (ICG) fluorescence imaging, allows for superior visualization and accuracy in complex surgeries and ultimately improves patient care and surgical efficacy.

講師:盧勝男教授。高雄長庚紀念醫院。胃腸肝膽科

講題: Clinical Issues of Two Hepatoma Seral Markers: PIVKA-II and AFP

摘要:肝癌血清標記PIVKA-II(異常凝血酶元)或稱Des-γ- Carboxy-Prothrombin (DCP)醫師使用經驗不如胎兒蛋白(AFP)豐富。分享PIVKA-II與AFP合併使用作為肝癌標記的臨床議題，可能有助於肝癌標記的適當使用。